DIR Return Create A Forum - Home
---------------------------------------------------------
Camelot Fantasies
HTML https://castleknights.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: PENNY STOCK UNIVERSE
*****************************************************
#Post#: 13314--------------------------------------------------
Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 5:06 pm
---------------------------------------------------------
Welcome to the Abbatis Bioceuticals Royal Hall.
Here we will share and list information about this great
Vancouver based Bioceutical firm that is at the forefront in
then the cannabis space.
Please post away and fun.
#Post#: 13315--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 5:08 pm
---------------------------------------------------------
here is a link to Abbatis Bioceuticals website:
HTML http://www.abattis.com/s/home.asp
much more information and charts to follow.
#Post#: 13316--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 5:15 pm
---------------------------------------------------------
I have added breaking news ticker about medical marijuana at the
top of the page.
to get the full article just click on the headline. it blinks
every 8 seconds.
I will add 2-3 more breaking news tickers at the top. stay
tuned.
this is current and breaking news.
#Post#: 13318--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 5:25 pm
---------------------------------------------------------
more news out today from Abbatis Bioceuticals Corporation:
Abattis Aims to Become Leader in Cannabis Testing with
Acquisition
April 8, 2014
by admin
Filled in: CannabisFN
Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT), a specialty
biotechnology company focused on cultivating, licensing and
marketing cannabis and related products and services, recently
announced the acquisition of a controlling 51% stake in
Washington-based Phytalytics LLC. The move could enable the
company to capitalize on the growing market for cannabis
compliance testing.
Under Washington State’s Initiative 502 Section 11, every
licensed marijuana producer and processor must submit
representative samples of marijuana, useable marijuana, or
marijuana-infused products produced or processed by the licensee
to an independent, third-party testing laboratory meeting the
accreditation requirements established by the WSLCB for
inspection and testing.
Dr. Michelle Sexton, Founder and CEO of Phytalabs, was
instrumental in developing the checklist and protocols for the
certification process for an analytics lab for the WSLCB that
approves state licensing of adult and medicinal marijuana. Dr.
Sexton was also the editor and technical advisor of American
Herbal Pharmacopoeia and a board member of the Americans for
Safe Access Foundation.
Other members of the Phytalabs team also have extensive industry
experience that should prove invaluable. Dr. Kaleb Lund, Science
Director of Phytalabs, has 10 years of analytical testing
experience in the herbal supplements industry, while Ms. Lauren
Hilty, CPA, Treasurer and Accountant, has been a consultant with
the Federal Depository Insurance Corporation (“FDIC”) to
establish marijuana banking rules.
Currently, Phytalytic is in the process of making an application
to the WSLCB for an analytics laboratory testing license in
order to provide government mandated testing of cannabis and all
other cannabis related derivatives. While the company hasn’t
provided guidance in terms of a timeline, the team’s background
suggests that the approval process could happen soon rather than
later.
Shares of Abattis are trading up 1.8% mid-way through Tuesday’s
session and up more than 86% over the past month.
CannabisFN.com, owned by TDM Financial, is a leading provider of
cannabis news and insights. CannabisFN.com may be compensated
for its services in the form of cash-based compensation or
equity securities in the companies it writes about, or a
combination of the two. View Full Disclaimer
#Post#: 13336--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Wingswomennbeer Date: April 8, 2014, 7:35 pm
---------------------------------------------------------
G ' afternoon ClayDeath, happy to contribute here
#Post#: 13337--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 7:38 pm
---------------------------------------------------------
welcome to Camelot Wingswomennbeer. I am glad you found Camelot.
we can all stay in touch and al keep sharing with the world info
about Abbatis Pharmaceutical Corporation.
thanks so much for your support.
#Post#: 13339--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 7:39 pm
---------------------------------------------------------
this is an awesome site.
you start to notice Abattis Pharmaceutical the second you click
on this link:
HTML http://www.cannabisfn.com/
#Post#: 13346--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 7:50 pm
---------------------------------------------------------
ATT:CNX; ATTBF:OTC
Shares Outstanding… 47.6M
Abattis remains a top pick out on the West Coast in the Medical
Marijuana scene. I have ATT/ATTBF firmly entrenched in the MMJ
sector and expect Abattis to follow a track similar to PLPL.
Yes I have said PLPL is a top recreation pick, but PLPL is one
of the few companies that I think will transcend both recreation
and medical cannabis. Abattis has methodically developed a
plan of attack and is now executing on that plan.
•Received their controlled substances licence which allows them
to develop extracts, concentrates and oils from the cannabis
they grow.
•Expanded into the US markets developing strategic alliances
with companies like Transbyte ERBB
•Owns arguably the top one of the top vegetable concentration
technologies which can be readily applied to cannabis.
•Own Vertical Designs, a patented vertical growing technology
they plan on licencing to other growers. Vertical Designs
growing technology maximizes space and light efficiencies
allowing for the greatest yields of indoor hydroponics systems.
Abattis has emerged as the market leader out west and is
entrenching themselves as one of the top medical cannabis
companies in North America, let alone Canada.
#Post#: 13369--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 8, 2014, 8:54 pm
---------------------------------------------------------
breaking news on Abbatis for those who may have missed it:
HTML http://marijuanaindex.org/industry-news-item/
Abattis Completes Acquisiton Of Controlling Interest In
Phytalytics LLC
(via Thenewswire.ca)
VANCOUVER, BC / TNW-ACCESSWIRE / April 7 , 2014 / Abattis
Bioceuticals Corp. ("Abattis" or the "Company") (CSE: ATT) (OTC:
ATTBF), a specialty biotechnology company with capabilities
through its wholly owned subsidiaries of cultivating, licensing
and marketing proprietary ingredients, bio-similar compounds,
patented equipment and consulting services to medicinal markets
in North America, today announced that further to its previous
press release dated March 6, 2014 disclosing it had entered into
consulting agreements with the principals of Phytalytics LLC of
Kirkland, Washington, USA, the Company has acquired a 51%
membership interest in Phytalytics LLC (doing business as
Phytalab.com ).
Phytalytics and its principals, Dr. Michelle Sexton, Dr. Kaleb
Lund and Lauren Hilty, Sr. Accountant, will be making an
application to the Washington State Liquor Control Board
("WSLCB") for an analytics laboratory testing license in order
to provide government mandated testing of cannabis and all other
cannabis related derivatives under State Initiative 502. Under
State Initiative 502 Section 11, every licensed marijuana
producer and processor must submit representative samples of
marijuana, useable marijuana, or marijuana-infused products
produced or processed by the licensee to an independent,
third-party testing laboratory meeting the accreditation
requirements established by the WSLCB, for inspection and
testing to certify compliance with standards adopted by the
WSLCB.
Dr. Sexton has long advocated for improved quality assurance for
herbal products and was a technical advisor for American Herbal
Pharmacopoeia on the "Cannabis Monograph: Standards on Identity,
Analysis and Quality Control."
HTML http://www.herbal-ahp.org/
Dr. Sexton recently consulted to the Washington State Liquor
Control Board for development of the certification process for
laboratories that provide analysis of Cannabis and related
products distributed under SI502. Phytalytics was developed on
the platform of Good Laboratory Practice (GLP) guidelines, which
Dr. Sexton introduced to the Cannabis industry. The combined
botanical and scientific backgrounds of Drs Sexton and Lund,
along with the partnership and expertise of Abattis, leverage
PhytaLab to continue to be pace setters in this burgeoning
industry.
Drs. Lund and Sexton, of Phytalytics, stated, "We are very
pleased to leverage our combined botanical and scientific
backgrounds with the expertise of Abattis so that PhytaLab will
continue to be a pacesetter in this burgeoning industry."
Mike Withrow, CEO of Abattis Bioceuticals Corp., stated, "We are
delighted to be able to consolidate and align the membership
interests in Phytalytics and looking forward to a mutually
beneficial relationship. Moving forward, our new analytics lab
testing team in Washington will have the support of the
Company's resources to secure a WSLCB license in addition to
sourcing the requisite equipment to scale its operations as
demand for its services escalate."
About Phytalytics LLC..
Phytalytics was founded in 2011 and pioneered the movement to
help define quality control of Cannabis and related products in
Washington State. PhytaLab is an industry leader with regard to
experience and validation know-how of in State mandated testing
of Flowers, Extracts, Edibles, Liquids, Topicals of Cannabis and
Cannabinoids. PhytaLab has taken great care to maximize HPLC
resolution so there is no overlap of compounds guaranteeing
accurate potency measurements, foreign material inspection,
moisture content, Microbiological Screening and Residual
Solvents Testing.
PhytaLab utilizes high-performance liquid chromatography (HPLC)
to separate and quantify the relevant cannabinoids in samples.
It is the most accurate, optimal and straightforward method for
analysis of the authentic plant compounds, including acidic and
neutral forms. This platform is the standard for testing of
compounds that can change upon heating, and therefore does not
heat the sample before analysis. For more information, visit the
Company's website at www.phytalab.com
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities
through its wholly owned subsidiaries of cultivating, licensing
and marketing proprietary ingredients, bio-similar compounds,
patented equipment and consulting services to medicinal markets
in North America. The Company is positioned to capitalize on the
fast growing trend toward marijuana legalization in the United
States and for medicinal use in Canada and international
jurisdictions by supplying and partnering with companies to
employ its vertical cultivation systems, extraction
equipment/technology, and strategic marketing support to
licensed growers. The Company also has an extensive pipeline of
high-quality products and intellectual property for the rapidly
expanding botanical drug market. We follow strict standard
operating protocols and adhere to the applicable laws of Canada
and foreign jurisdictions. For more information, visit the
Company's website at www.abattis.com.
For further information, contact the Company's CEO, Michael
Withrow at (778) 896-6536 or at mike.withrow@abattis.com.
ON BEHALF OF THE BOARD
"Mike Withrow"_____________
Mike Withrow
President & CEO
For information please contact:
Mike Withrow
P: 778.896.6536
www.abattis.com
#Post#: 13482--------------------------------------------------
Re: Welcome To The Abbatis Bioceuticals Royal Hall
By: Clay Death Date: April 10, 2014, 6:47 pm
---------------------------------------------------------
this news today from Abbatis is simply massive. it got lost in
all that blood bath today.
well it wont be lost much longer. tomorrow the world will find
out about it.
HTML http://marijuanaindex.org/industry-news-item/
April 10, 2014 - 9:15 AM EDT
Abattis Announces Completes Agreement With Experion
(via Thenewswire.ca)
Vancouver, BC - April 10th, 2014 - Abattis Bioceuticals Corp.
(the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT),
through its wholly owned subsidiary, Northern Vine Canada Inc.
("Northern Vine"), announces that it has entered into a share
exchange agreement with Experion Biotechnologies Inc.
("Experion"). Pursuant to the terms of the agreement, Experion
and Northern Vine have exchanged 25% of each parties' issued and
outstanding common shares. Abattis maintains a 75% ownership in
Northern Vine.
Experion is located in Greater Vancouver and is nearing the
completion of its Marijuana for Medical Purposes Regulations
"MMPR" licence application with Health Canada. Together,
Northern Vine and Experion are well positioned to capitalize on
the growing trend towards marijuana legalization in the U.S.,
and medical use in Canada as licensed producers.
Northern Vine, a lab and compounding pharmacy with patented
compositions, owns various Natural Health Product licenses for
use in the nutraceutical markets. Northern Vine has one
remaining outstanding item to complete as required by Health
Canada in respect of its controlled substance licence
application.
It is anticipated that Experion will provide cannabis for
Northern Vine's research and development activities upon
receiving its MMPR licence. Experion will also allocate a
portion of its 10 acre site for the expansion of Northern Vine's
future processing facility and any expansion requirements needed
to satisfy cultivation demand in the foreseeable future.
Mike Withrow, President and CEO of Abattis stated: "This is a
strategic partnership that links our pending Controlled
Substance Licence to another MMPR Application in order to
further expand our business potential. This agreement provides
the Company with more control of a broader variety of raw
materials, for products derived from marijuana, to be processed
at our planned botanical drug facility in Quebec. This
partnership also creates synergy by joining cultivation with
formulation sciences."
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities
through its wholly owned subsidiaries of cultivating, licensing
and marketing proprietary ingredients, bio-similar compounds,
patented equipment and consulting services to medicinal markets
in North America. The Company is positioned to capitalize on the
fast growing trend toward marijuana legalization in the United
States and for medicinal use in Canada and international
jurisdictions, by supplying and partnering with companies to
employ its vertical cultivation systems, extraction
equipment/technology, and strategic marketing support to
licensed growers. The Company also has an extensive pipeline of
high-quality products and intellectual property for the rapidly
expanding botanical drug market. We follow strict standard
operating protocols, and adhere to the applicable laws of Canada
and foreign jurisdictions. For more information, visit the
Company's website at: www.abattis.com.
About Experion Biotechnologies Inc.
Experion Biotechnologies Inc. is a team of innovators dedicated
to producing, procuring, and providing medical products derived
from Cannabis of superior quality in a consistent and timely
manner to patients across Canada in accordance with Health
Canada regulations. Its current facilities in the Greater
Vancouver Area are ready to operate under strict guidelines with
standardized operating protocols as a commitment to the quality
patients require.
For further information, contact the Company's CEO, Michael
Withrow at (604) 538-6650
or at mike.withrow@abattis.com.
*****************************************************
DIR Next Page